IVES' CYCLOSPASMOL (CYCLANDELATE) DESI HEARING WILL BE HELD, FDA
IVES' CYCLOSPASMOL (CYCLANDELATE) DESI HEARING WILL BE HELD, FDA announced in an Oct. 19 Federal Register notice. A prehearing conference on Cyclospasmol caps and tabs containing cyclandelate is scheduled for Jan. 15, 1985, with notices of participation to be filed no later than Nov. 19. The hearing is in response to requests from the American Home Products subsidiary, as well as Cord Labs, Premo Pharmaceuticals and the Natl. Assn. of Pharmaceutical Mfrs. According to the notice, Ives "primarily relies upon two studies to support an indication for peripheral vascular disease, primarily in patients with arteriosclerosis obliterans . . . and three studies to support an indication for cerebral vascular disease." Noting that Ives "primarily relies upon only four" of 16 efficacy studies submitted for Cyclospasmol, FDA denied the firm's request for a hearing on the agency's 1981 revocation of exemption for the drug. McNeil's Parafon Forte will be the subject of another upcoming DESI hearing, FDA announced in a separate Federal Register notice Oct. 15. The prehearing conference for the chlorzoxazone/acetaminophen combination is set for April 2, 1985, with notices of participation to be filed no later than Nov. 14. In addition to McNeil, Purepac, Ferndale Labs, Danbury and Lemmon have requested a hearing on the agency's proposal to withdraw approval for the drug. In a third DESI notice published the week of Oct. 19, FDA announced the revocation of exemption and opportunity for a hearing on "certain single-entity coronary vasodilators containing pentaerythritol tetranitrate (PETN)." At least eight firms currently market the antianginals: Parke-Davis, Armour, Marion, Zenith, Bolar, Danbury, Phoenix's Vitarine division, Inwood Labs, and Vangard Labs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth